Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- 13 Nov 2019 Planned End Date changed from 31 Oct 2019 to 1 Mar 2021.
- 13 Nov 2019 Planned primary completion date changed from 31 Oct 2019 to 1 Mar 2021.
- 29 Jun 2018 Status changed from suspended to recruiting.